Cost effectiveness of postoperative carcinoembryonic antigen monitoring in colorectal cancer. 1984

R S Sandler, and D A Freund, and C A Herbst, and D P Sandler

Serial monitoring of carcinoembryonic antigen (CEA) has been thought to provide early indication of recurrent cancer in individuals who have undergone curative resection. The current study was designed to assess the costs associated with CEA monitoring. Costs included CEA determinations, other evaluative tests prompted by abnormal CEA values and hospital/surgical costs in patients undergoing "second-look" procedures. The authors estimated that the cost per resectable tumor was $24,779; but, under optimal circumstances, it might be as low as $10,446. The most important factors were the percentage of recurrent tumors and the proportion of these that were resectable. It proved slightly more efficient to limit the preoperative workup rather than to decrease the frequency of CEA determinations. The true benefits of CEA initiated second-look surgery in terms of prolonged survival remain unknown. More clinical experience is needed to better understand these benefits.

UI MeSH Term Description Entries
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010808 Physical Examination Systematic and thorough inspection of the patient for physical signs of disease or abnormality. Physical Exam,Examination, Physical,Physical Examinations and Diagnoses,Exam, Physical,Examinations, Physical,Exams, Physical,Physical Examinations,Physical Exams
D012004 Rectal Neoplasms Tumors or cancer of the RECTUM. Cancer of Rectum,Rectal Cancer,Rectal Tumors,Cancer of the Rectum,Neoplasms, Rectal,Rectum Cancer,Rectum Neoplasms,Cancer, Rectal,Cancer, Rectum,Neoplasm, Rectal,Neoplasm, Rectum,Rectal Cancers,Rectal Neoplasm,Rectal Tumor,Rectum Cancers,Rectum Neoplasm,Tumor, Rectal
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D005188 False Negative Reactions Negative test results in subjects who possess the attribute for which the test is conducted. The labeling of diseased persons as healthy when screening in the detection of disease. (Last, A Dictionary of Epidemiology, 2d ed) False Negative Reaction,Reaction, False Negative,Reactions, False Negative
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

R S Sandler, and D A Freund, and C A Herbst, and D P Sandler
January 1997, Arquivos de gastroenterologia,
R S Sandler, and D A Freund, and C A Herbst, and D P Sandler
July 1997, Diseases of the colon and rectum,
R S Sandler, and D A Freund, and C A Herbst, and D P Sandler
January 1980, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie,
R S Sandler, and D A Freund, and C A Herbst, and D P Sandler
December 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R S Sandler, and D A Freund, and C A Herbst, and D P Sandler
May 1981, Minerva chirurgica,
R S Sandler, and D A Freund, and C A Herbst, and D P Sandler
January 1998, Surgery today,
R S Sandler, and D A Freund, and C A Herbst, and D P Sandler
February 2021, Anticancer research,
R S Sandler, and D A Freund, and C A Herbst, and D P Sandler
October 1976, AJR. American journal of roentgenology,
R S Sandler, and D A Freund, and C A Herbst, and D P Sandler
January 1999, Current oncology reports,
R S Sandler, and D A Freund, and C A Herbst, and D P Sandler
January 1998, Arquivos de gastroenterologia,
Copied contents to your clipboard!